Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.

P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis. Based on the scaffold of a known P2Y12 antagonist AZD1283, a series of novel bicyclic pyridine derivatives were designed and synthesized. The cyclization of the ester substituent on the pyridine ring to the ortho-methyl group led to lactone analogues of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies. The metabolic stability was further enhanced by adding a 4-methyl substituent to the piperidinyl moiety. Compound 58l displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model. Moreover, 58l showed a safety profile that was superior to what was observed for clopidogrel in a rat tail-bleeding model. These results support the further evaluation of compound 58l as a promising drug candidate.

[1]  R. Katira,et al.  Cangrelor , 2019, Reactions weekly.

[2]  K. Peter,et al.  Current and future antiplatelet therapies: emphasis on preserving haemostasis , 2018, Nature Reviews Cardiology.

[3]  T. Talele.  The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. , 2016, Journal of medicinal chemistry.

[4]  F. Zetterberg,et al.  State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists. , 2016, Bioorganic & medicinal chemistry letters.

[5]  D. Renneberg,et al.  4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. , 2015, Journal of medicinal chemistry.

[6]  Qiang Zhao,et al.  Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information , 2015, Journal of Computer-Aided Molecular Design.

[7]  C. Tam,et al.  Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. , 2014, Blood.

[8]  J. Herbert,et al.  SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? , 2014, Thrombosis research.

[9]  J. Herbert,et al.  N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. , 2014, Journal of medicinal chemistry.

[10]  H. Zachrisson,et al.  Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations. , 2014, Bioorganic & medicinal chemistry letters.

[11]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[12]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[13]  E. Lev,et al.  Pharmacology of Antiplatelet Agents , 2013, Current Atherosclerosis Reports.

[14]  Jiaxi Xu,et al.  Convenient and Environment-Friendly Synthesis of Sulfonyl Chlorides from S-Alkylisothiourea Salts via N-Chlorosuccinimide Chlorosulfonation. , 2013 .

[15]  H. Zachrisson,et al.  Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283. , 2013, Journal of medicinal chemistry.

[16]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[18]  J. Macor,et al.  Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. , 2010, ACS medicinal chemistry letters.

[19]  A. Michelson.  Antiplatelet therapies for the treatment of cardiovascular disease , 2010, Nature Reviews Drug Discovery.

[20]  A. Kastrati,et al.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement , 2010, Journal of thrombosis and haemostasis : JTH.

[21]  H. Zachrisson,et al.  Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. , 2009, Thrombosis research.

[22]  F. Giordanetto,et al.  Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation , 2009, Journal of thrombosis and haemostasis : JTH.

[23]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[24]  N. Farid,et al.  Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  M. Cattaneo.  Platelet P2 receptors: old and new targets for antithrombotic drugs , 2007, Expert review of cardiovascular therapy.

[26]  Eric A. Barnard,et al.  International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy , 2006, Pharmacological Reviews.

[27]  E. John,et al.  Enaminones as building blocks in heterocyclic syntheses: A new approach to polyfunctionally substituted cyclohexenoazines , 2003 .

[28]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[29]  M. Seyfarth,et al.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.

[30]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.